C2 3'-Sulfo galactosylceramide (d18:1/2:0)

Catalog No. :
ACFBLF578
CAS No. :
252846-08-5
Molecular Formula :
C26H49NO11S
Molecular Weight :
583.74

IUPAC Name:(2R,3R,4S,5S,6R)-2-(((2S,3R,E)-2-acetamido-3-hydroxyoctadec-4-en-1-yl)oxy)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-4-yl hydrogen sulfate

C2 3'-Sulfo galactosylceramide (d18:1/2:0) structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameC2 3'-Sulfo galactosylceramide (d18:1/2:0)
IUPAC Name(2R,3R,4S,5S,6R)-2-(((2S,3R,E)-2-acetamido-3-hydroxyoctadec-4-en-1-yl)oxy)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-4-yl hydrogen sulfate
Molecular FormulaC26H49NO11S
Molecular Weight583.74
SMILESO=S(O)(O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(C)=O)[C@H](O)/C=C/CCCCCCCCCCCCC)O[C@H](CO)[C@@H]1O)=O
InChI KeyMVKSJJXQJVKQHP-MSZSJPIVSA-N
SynonymC2 3'-sulfo Galactosylceramide (d18:1/2:0);-sulfo Galactosylceramide (d18:1/2:0);C2 3’Acetamide, N-[(1S,2R,3E)-2-hydroxy-1-[[(3-O-sulfo-β-D-galactopyranosyl)oxy]methyl]-3-heptadecen-1-yl]-;N-Acetyl-sulfatide;N-[(1S,2R,3E)-2-hydroxy-1-[[(3-O-sulfo-β-D-galactopyranosyl)oxy]methyl]-3-heptadecen-1-yl]-acetamide;C2 3′,-sulfo Galactosylceramide (d18:1/2:0)
CAS No.252846-08-5

Synthetic Route by SureRoute

1. ACFBLF578 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACFBLF578 route product structure diagram
    ACFBLF578252846-08-5
Inquiry

2. ACFBLF578 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACFBLF578 route product structure diagram
    ACFBLF578252846-08-5
Inquiry

Comments (0)